Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31159145 | 1.00 | DPP4 (0.47) | DPP4ALDH1A1KDM4EHSD17B10SORT1 | |
| SCHEMBL3829091 | 0.86 | DPP4 (0.50) | DPP4ALDH1A1KDM4EHSD17B10SORT1 | |
| SCHEMBL18329485 | 0.85 | MEN1 (0.45) | ALDH1A1KDM4ENOTUMMEN1KMT2A | |
| SCHEMBL31193466 | 0.82 | DPP4 (0.60) | DPP4ALDH1A1KDM4EHSD17B10SORT1 | |
| SCHEMBL20780583 | 0.81 | MEN1 (0.42) | NOTUMCLCN2ADRA2AMEN1KMT2A | |
| SCHEMBL4638190 | 0.81 | ALDH1A1 (0.52) | DPP4ALDH1A1KDM4EHSD17B10NOTUM | |
| SCHEMBL8090741 | 0.81 | DPP4 (0.48) | DPP4ALDH1A1KDM4EHSD17B10NOTUM | |
| SCHEMBL28759223 | 0.79 | DPP4 (0.69) | DPP4ALDH1A1KDM4EHSD17B10MEN1 | |
| SCHEMBL1495242 | 0.79 | CYP3A4 (0.44) | ALDH1A1NOTUMMEN1KMT2AMAPK1 | |
| SCHEMBL27292205 | 0.79 | KDM4E (0.46) | ALDH1A1KDM4EHSD17B10NOTUMCLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2022235575-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2021096948-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021028645-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028649-A1 | PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | DPP4 1125/4885ALDH1A1 4739/4885KDM4E 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.